GALT earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E -8.60. Updated 2026-07-23.
Galectin Therapeutics (GALT) Research Hub
Galectin Therapeutics (GALT) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 3.91 USD (-3.46%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -8.60, market cap 0.24B. This hub links to the full technical, earnings and options research available for GALT.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 3.91 USD (-3.46%) |
| 52-week range | 2.58 USD – 5.39 USD |
| Trend regime | Range |
| 14-day RSI | 58.2 (Bullish) |
| Trailing P/E | -8.60 |
| Market cap | 0.24B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for GALT
Covered Call on GALT: how it works, illustrative setup around the real 3.91 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on GALT: how it works, illustrative setup around the real 3.91 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on GALT: how it works, illustrative setup around the real 3.91 USD price, max profit/loss, breakeven and when to use it. Educational.
GALT technical analysis: range, last 3.91 USD, RSI 58.2, 52w range 2.58 USD–5.39 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is GALT in?
Galectin Therapeutics (GALT) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is GALT in an uptrend or downtrend?
As of 2026-09-11, GALT is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is GALT's trailing P/E ratio?
GALT's trailing P/E is -8.60, with a market cap of 0.24B. See the earnings research page for full valuation detail.
When does GALT next report earnings?
GALT is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -0.09 USD.